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Summary
Although mosaicism can have important implications
for genetic counseling of families with hereditary dis-
orders, information regarding the incidence of mosai-
cism is available for only a few genetic diseases. Here
we describe an evaluation of 156 families with retino-
blastoma; the initial oncogenic mutation in the retino-
blastoma gene had been identified in these families. In
15 (∼10%) families, we were able to document mosai-
cism for the initial mutation in the retinoblastoma gene,
either in the proband or in one of the proband’s parents.
The true incidence of mosaicism in this group of 156
families is probably higher than our findings indicate; in
some additional families beyond the 15 we identified,
mosaicism was likely but could not be proven, because
somatic or germ-line DNA from key family members
was unavailable. Germ-line DNA from two mosaic fa-
thers was analyzed: in one of these, the mutation was
detected in both sperm and leukocyte DNA; in the other,
the mutation was detected only in spermDNA.Our data
suggest that mosaicism is more common than is generally
appreciated, especially in disorders such as retinoblas-
toma, in which a high proportion of cases represent new
mutations. The possibility of mosaicism should always
be considered during the genetic counseling of newly
identified families with retinoblastoma. As demonstrated
here, genetic tests of germ-line DNA can provide valu-
able information that is not available through analysis
of somatic (leukocyte) DNA.
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Introduction
Retinoblastoma is a malignant tumor of the retina that
arises predominantly in children !7 years of age. It
affects 1/23,000–1/16,000 live births (McLean 1996).
Retinoblastoma has served as a prototype for hereditary
cancer, in part because the genetics of the disease is ex-
plained by the action of a single gene, the retinoblastoma
gene (RB1 [MIM 180200]), within chromosome band
13ql4. Retinoblastomas arise only from retinal cells that
have lost the function of both allelic copies of RB1. The
initial mutation, which affects one RB1 allele, can be in
a patient’s germ line, in which case the patient is clas-
sified as having hereditary retinoblastoma. Patients with
hereditary retinoblastoma can transmit the initial mu-
tation and the corresponding predisposition to retinob-
lastoma as a dominant Mendelian trait. Alternatively,
the initial mutation can arise in retinal cells or their
embryonic precursors and not involve the germ line. This
is the genetic basis for nonhereditary retinoblastoma.
Regardless of whether the initial mutation is inherited
or arises somatically, the retinal cells that carry it can
become malignant only if they also lose the remaining
normal copy of RB1. This loss of the second functional
RB1 allele can be due to a separate somatic mutation
(∼30% of tumors [Kato et al. 1993]), hypermethylation
(a small percentage of tumors [Greger et al. 1994; Oht-
ani-Fujita et al. 1997]), or loss of heterozygosity at syn-
tenic loci, including RB1, over a large segment of 13q
(∼70% of tumors). The loss of heterozygosity occurs
through mitotic recombination, mitotic nondisjunction,
or a large deletion (Cavenee et al. 1983; Godbout et al.
1983; Dryja et al. 1984). The rate of loss of the second
allele, through mutation or other mechanisms, is high
enough among fetal and infantile retinal cells to ensure
that at least one retinoblastoma develops in 190% of
patients with an inherited initial mutation. Nonpene-
trant (i.e., unaffected) carriers are either individuals who
possess an initial mutation but in whom, fortuitously,
no sensitive retinal cell loses the remaining wild-type
RB1 allele, or individuals who have an initial RB1 mu-
tation with partial function (Sakai et al. 1991a; Onadim
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et al. 1992; Dryja et al. 1993; Kratzke et al. 1994; Loh-
mann et al. 1994; Cowell et al. 1996; Sterner et al. 1996;
Bremner et al. 1997; Schubert et al. 1997).
Studies of the proportion of affected offspring of ret-
inoblastoma patients who survive to adulthood have
prompted geneticists to place all multifocal cases (either
bilateral or unilateral) into the hereditary retinoblastoma
category (Vogel 1979). Most multifocal cases are not
associated with a family history of retinoblastoma, and
these are assumed to represent new germ-line mutations.
Unilateral (unifocal) cases associated with a positive
family history are also considered to be hereditary re-
tinoblastoma. Unilateral cases that are not associated
with a previous family history of retinoblastoma can be
in either the nonhereditary or the hereditary category
(Briard-Guillemot et al. 1974; Vogel 1979). The pro-
portion of unilateral, simplex cases that involve an initial
mutation in the germ line has been estimated to be∼12%
(Vogel 1979).
These categorizations underemphasize the possibility
of mosaicism for the initial mutation either in the first
affected individual in a family or in one of the parents
of such a proband. Mosaicism can occur when a mu-
tation in RB1 arises at some point during embryogenesis;
the point at which the mutation occurs during embry-
ogenesis determines the degrees to which the various
tissues carry the defect. Whereas it is usually assumed
that the initial RB1 mutation is present either in all cells
(the “hereditary” type of retinoblastoma) or in only the
retinal cell that immediately precedes the progenitor tu-
mor cell (the “nonhereditary” type), a mosaic individual
may have the initial mutation gene in some but not all
cells, distributed among many tissue types. Significant
errors can result when mosaicism is not considered dur-
ing genetic counseling (Hall 1988; Paller et al. 1994).
Mosaicism and its effect on genetic counseling have been
described for a number of autosomal dominant and X-
linked disorders, including neurofibromatosis (La´zaro et
al. 1994) and Duchenne muscular dystrophy (Bakker et
al. 1987, 1989; Passos-Bueno et al. 1990). However,
very little information is available regarding the inci-
dence of mosaicism in retinoblastoma and the degree to
which genetic counseling should therefore be modified
to account for it. We set out to determine how often
mosaicism could be documented in a group of families
that included one or more individuals affected with
retinoblastoma.
Methods
This research was performed in accordance with the
Declaration of Helsinki and was approved by the Hu-
man Studies Committees of the Massachusetts Eye and
Ear Infirmary and Harvard Medical School. Cases were
derived from a clinical laboratory (the Ophthalmic Ge-
netics Laboratory at the Massachusetts Eye and Ear In-
firmary) that provides genetic testing for retinoblastoma.
Blood samples were obtained from retinoblastoma pa-
tients and their relatives at the Massachusetts Eye and
Ear Infirmary and at other institutions. In many cases,
tumor samples were obtained from affected eyes that
had been enucleated as part of the treatment of the pa-
tients. Semen samples were obtained from unaffected
fathers in families 139 and 262 only.
Blood samples were transported at room temperature,
and tumor and semen samples were transported on dry
ice. For semen samples, half of each sample was purified
over a discontinuous Percoll column, and the other half
was not (McClure et al. 1989; Ord et al. 1990). Puri-
fication over a Percoll column was designed to remove
nonmotile cells—specifically, nonsperm cells. Each se-
men and purified-sperm sample was mixed with an equal
amount of test yolk buffer medium (Irvine Scientific)
prior to freezing and transport. DNA was purified from
leukocyte nuclei, unfixed tumor fragments, semen, or
purified sperm by standard methods that included treat-
ment with proteinase K, phenol-chloroform extraction,
and ethanol precipitation. DNA was stored in 10 mM
Tris, pH 7.7, 1 mM EDTA, at 1–10C, for X15 years
before analysis.
Five intragenic polymorphisms were analyzed to de-
termine the transmission of alleles within families and
to determine whether, in each tumor, an RB1 allele was
lost. These polymorphisms were a BamHI RFLP in in-
tron 1 (Bookstein et al. 1988), a SacI RFLP in intron 2
(Sakai et al. 1991b; Rothberg et al. 1997), an XbaI RFLP
in intron 17 (McGee et al. 1990), a VNTR in intron 17
(Wiggs et al. 1988), a tetranucleotide-repeat polymor-
phism in intron 20 (Yandell and Dryja 1989), and a
Tth111I RFLP in intron 24 (Vaughn et al. 1990). The
haplotypes deduced from the analysis of these poly-
morphisms were labeled with letters specific for each
family. In family 26, additional RFLP markers on chro-
mosome 13 were examined to verify the designated pa-
ternity (Squire et al. 1986; Scheffer et al. 1989).
Southern blot analysis with cDNA and genomic
probes derived from the retinoblastoma locus was used
to screen for gene deletions or rearrangements (Wiggs
et al. 1988). Point mutations and small deletions or in-
sertions that are beyond the resolution of Southern blot
techniques were identified by means of exon-by-exon
SSCP and direct genomic-sequencing techniques (Yan-
dell et al. 1989; Hogg et al. 1992; Shimizu et al. 1994).
The mutation in family 452 was discovered by direct
genomic sequencing, after the size and copy number of
all exons were found to be normal by multiplex PCR.
Mutations are specified in this article in accordance with
the numbering scheme of the RB1 sequence in the Ge-
nome Database (http://www.gdb.org; accession number
L11910) (Toguchida et al. 1993). For all tumors that
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Figure 1 Pedigrees of families with one member in whom mo-
saicism could be documented. The family identification number ap-
pears at the upper left of each pedigree. A blackened symbol indicates
an individual affected with bilateral retinoblastoma; a half-blackened
symbol indicates an individual affected with unilateral retinoblastoma.
The letters below each individual indicate the haplotypes at the RB1
locus in leukocyte DNA; letters under the word “TUMOR” indicate
the haplotypes that were found in tumor DNA. Alleles at intragenic
polymorphisms were used to deduce haplotypes; in each family, the
haplotypes were labeled alphabetically, beginning with those found in
the father (unless the father was not analyzed). No haplotype letters
appear below individuals who were not analyzed. An asterisk (*) or
a small circle () indicates an allele with a mutation; the mutations to
which these symbols refer are noted below each pedigree. The abbre-
viation “del” designates a deletion of the entire RB1 gene, as revealed
by Southern blotting, unless otherwise indicated. A plus sign () (fam-
ily 271) indicates a normal chromosome 13, determined by karyotyp-
ing; no DNA analysis was performed on these individuals. Each ped-
igree is described in the text.
had loss of heterozygosity, the intensities of RB1 gene
fragments on Southern blots were evaluated, to deter-
mine whether the initial mutation was hemizygous (i.e.,
the second allele was deleted) or homozygous (i.e., the
tumor was isodisomic for the initial mutation).
In some cases, quantitation of the proportion of nor-
mal DNA to mutant DNA in blood and sperm samples
was performed. Two quantitation methods were used.
The first method involved visual comparison of the in-
tensities of the normal and mutant SSCP bands, in the
sample of interest, to a scale that was constructed by
mixing known quantities of DNA from samples with
and from samples without the mutation. The second
method was performed with computer software (IM-
AGE WORKS [MacIntosh version], PDI) that was used
to measure the intensities of bands from digitized images
that were obtained by means of a scanner.
Results
We reviewed records of 405 families who had under-
gone DNA analysis of RB1 because at least one family
member was affected with retinoblastoma. In 156 fam-
ilies, an initial mutation had been identified. In 80 of
the 156 families, the first affected individual had uni-
lateral retinoblastoma (11 from multiplex families), and
in 76 families, the first affected individual had bilateral
retinoblastoma (8 frommultiplex families). Inmost cases
the initial mutation was unambiguously recognized, ei-
ther because it was detected in leukocyte DNA of an
affected individual or because it was found to be ho-
mozygous in tumor DNA. In a few cases, the initial
mutation was known only as one of two separate het-
erozygous mutations, identified in tumor DNA, that pre-
sumably represent heteroalleles; in each of these cases,
neither mutation was in the leukocyte DNA from the
patient, so we could not determine which of the two
was the initial mutation. However, this ambiguity did
not affect the assessment of mosaicism in any of these
cases. We included eight isolate cases in which the tu-
mors appeared to be due to homozygous hypermethy-
lation of the promoter region of RB1. In reports of these
and other such cases, mosaicism for aberrant hyper-
methylation of RB1 has never been found, and hyper-
methylation of RB1 has never been transmitted through
the germ line (Ohtani-Fujita et al. 1997). We did not
include five families with low-penetrance retinoblas-
toma, because the families were so large that the founder
could not be identified (three of these families had the
missense mutation Arg661Trp [Onadim et al. 1992;
Lohmann et al. 1994], one had a mutation in the pro-
moter region [Sakai et al. 1991a], and one had a deletion
of exon 4 [Dryja et al. 1993]).
Of the 156 families with an identified initial mutation,
a mosaic member could be documented in 15 (∼10%).
In six families, the mosaic member was an unaffected
parent, and in nine families, the mosaic member was the
first affected individual (seven affected bilaterally and
two affected unilaterally). Nine mosaic individuals were
males and five were females (in family 296, the sex of
the mosaic member, who was either the father or the
mother, was undetermined). Figure 1 displays schematic
pedigrees of these cases and illustrates the transmission
of RB1 alleles. The cases are summarized below, in
groups with similar clinical characteristics.
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Bilateral Simplex Retinoblastoma without Initial
Mutation Detected in Leukocyte DNA (Families 294,
377, and 266)
In family 294, unaffected parents gave birth to a child
who was initially diagnosed at age 18 mo with unilateral
retinoblastoma. The affected eye was enucleated. South-
ern blot analysis of tumor DNA revealed a homozygous
deletion of the entire RB1 gene. Analysis of leukocyte
DNA revealed that the affected child had inherited non-
deleted alleles from both the father and the mother; this
finding suggested nonhereditary retinoblastoma. At a
follow-up eye examination, when the child was 37 mo
of age, a tumor was found in the fellow eye; this tumor
was successfully treated without enucleation.
In family 377, unaffected parents gave birth to a child
who developed bilateral retinoblastoma. Analysis of the
child’s tumor DNA revealed both erroneous hyper-
methylation of the promoter region (a somatically aris-
ing, epigenetic defect that inactivatesRB1 [Ohtani-Fujita
et al. 1993; Greger et al. 1994; Ohtani-Fujita et al.
1997]) and the frameshift mutation Va1368(1bp del)
(65417delT). Both gene defects were heterozygous in the
tumor and were presumably allelic. Analysis of the pa-
tient’s leukocyte DNA revealed neither gene defect.
The index patient in family 266 also had bilateral
retinoblastoma and no family history of the disease.
Analysis of the child’s tumor DNA revealed the ho-
mozygous frameshift mutation Ser634(2bp ins)
(153295insTC). This mutation was not detected in the
patient’s leukocyte DNA.
Cases of Retinoblastoma with an Initial Mutation Is
Detected in Only a Fraction of Leukocytes (Families 7,
344, 26, 218, 333, and 452)
In family 7, unaffected parents gave birth to a child
who was affected with bilateral retinoblastoma.Analysis
of the child’s tumor DNA revealed a deleted paternal
allele at the RB1 locus; no defect in the maternal allele
has yet been identified. Analysis of leukocyte DNA re-
vealed an undeleted paternal allele, but the concentra-
tion was markedly lower than that of the maternal allele.
In family 344, analysis of tumor DNA from a child
affected with unilateral retinoblastoma revealed a ho-
mozygous nonsense mutation, designated Arg251End
(59683CrT). Analysis of the child’s leukocyte DNA
demonstrated the presence of the mutation, but the ratio
of mutant to wild-type sequence was less than the 50:
50 ratio expected for a heterozygote.
In family 26, two unaffected children inherited dif-
ferent alleles from a bilaterally affected father. Mutation
analysis revealed a frameshift mutation, Lys329(1-bp
del) (64377delA), in the father’s leukocyte DNA, but at
a level that was less than the 50% expected for a het-
erozygote. This mutation could not be detected in the
DNA of either child. Results of analysis of four addi-
tional polymorphic sites on chromosome 13 were con-
sistent with the designated paternity.
The bilaterally affected father in family 218 had the
mutation IVS192(1-bp ins) (153355insG), which was
detected in his leukocytes at a level that was less than
the 50% expected for a heterozygote. He had passed the
mutation to his second daughter, who also developed
bilateral retinoblastoma.
In family 333, a father affected with unilateral reti-
noblastoma had four children, one of whom developed
bilateral retinoblastoma. Mutation analysis revealed a
frameshift mutation, Ala628(2-bp del) (153276delCA),
that was heterozygous in the affected child’s leukocytes
and homozygous in the child’s tumor. Examination of
the father’s leukocyte DNA revealed the same mutation;
however, the ratio of mutant to wild-type sequence was
less than the 50:50 ratio expected for a heterozygote.
Analysis of intragenic DNA polymorphisms indicated
that the father had passed the same gene homologue to
two unaffected, noncarrier children and to the affected,
carrier child.
In family 452, a mother affected with bilateral reti-
noblastoma had passed the same haplotype to three chil-
dren, only one of whom developed bilateral retino-
blastoma. Leukocytes from the affected child carried the
heterozygous nonsense mutation Arg320End
(64348CrT). The mother also displayed the mutation
in her blood, but the ratio of mutant to wild-type se-
quence was less than the 50:50 ratio expected for a het-
erozygote (fig. 2). The unaffected children had no evi-
dence of the mutation in their leukocyte DNA, yet two
of them had inherited the same gene homologue, as de-
termined by analysis of intragenic RFLPs.
Affected Siblings Inherit the Same Mutation from an
Unaffected Parent, and the Mutation Is Not Detected
in the Parent’s Leukocyte DNA (Families 262, 296,
and 271)
In family 262, unaffected parents gave birth to three
daughters, one of whom had retinoblastoma that in-
volved the pineal gland and both eyes (trilateral reti-
noblastoma [Bader et al. 1982]), and another of whom
had bilateral retinoblastoma. Both affected children het-
erozygously carried the nonsense mutation Arg556End
(78250CrT) in their leukocyte DNA. RFLP analysis
showed that both affected daughters had inherited the
same paternal haplotype but different maternal haplo-
types; their unaffected sibling had also inherited the same
paternal haplotype, but she did not carry the nonsense
mutation. The mutation could not be detected in the
leukocyte DNA from either parent, but it was detected
in the father’s purified sperm DNA, at a level that in-
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Figure 2 SSCP analysis of the nonsense mutation Arg320End,
in family 452. The results of analysis of leukocyte DNA from each
individual appear directly below that person’s symbol. Numerous
bands are present because the amplified fragment was digested with
an endonuclease before SSCP analysis. The mutant fragment is indi-
cated with an arrow at the lower right. The intensity of the mutant
fragment in the mother (blackened circle) is less than in her affected
son (blackened square); this reduction in intensity was also observed
in quantitative sequencing (data not shown).
Figure 3 SSCP analysis of the nonsense mutation Arg556End,
in family 262. The results of analysis of blood (leukocyte) DNA from
each individual are located directly below that person’s symbol, except
for the father (unblackened square, upper left), under whose symbol
are lanes B and S, which show results from leukocyte and purified
sperm DNA, respectively. The lanes under the terms “10%,” “5%,”
and “2%” show results from mixtures of wild-type and mutant DNA
(derived from the mother and the younger affected daughter, respec-
tively) that would contain the indicated proportions of mutant and
wild-type alleles. On the basis of these scaling lanes, we estimate the
proportion of mutant sperm to be ∼5%.
dicated that ∼5% of the sperm carried the mutation (fig.
3).
In family 296, unaffected parents gave birth to two
children affected with bilateral retinoblastoma (one since
deceased), as well as six unaffected children. The mu-
tation, Gln575End (150025CrT), was detected in the
blood of one of the affected children; blood from the
deceased child was not available. The mutation was not
detected in the blood of either parent.
In family 271, unaffected parents gave birth to three
children. The first child had unilateral retinoblastoma,
the second had mental retardation and facial dysmorph-
ism, and the third was without retinoblastoma, mental
retardation, or dysmorphism. Karyotype analysis re-
vealed a deletion of 13q14 in the first two children
(46,XX,del[13][q14.2q14.3]); the third child had a nor-
mal karyotype. Analysis of leukocyte DNA, from the
parents and from the child affected with retinoblastoma,
revealed that the mutant chromosome was maternal in
origin but that the mother did not have it in a sufficient
proportion of cells to reduce the intensity of either of
the allelic fragments at a microsatellite polymorphism
within RB1. Chromosome analysis of the mother was
not performed.
An Affected Child Inherits a Mutation from an
Unaffected Parent, and the Mutation Is Detected in
Only a Fraction of the Parent’s Leukocytes (Families
139, 385, and 345)
In family 139, unaffected parents gave birth to three
children, one of whom developed bilateral retinoblas-
toma. Analysis of a tumor from the affected child re-
vealed two presumably allelic mutations. One was a de-
letion that extended off the 5′ end of the gene and
eliminated exon 1; the second was a frameshift,
Arg467(11-bp ins), that resulted from a duplication of
11 bp in exon 15 (76900insATTATCCATTC). The
frameshift mutation was present in the affected child’s
leukocyte DNA, but the deletion of exon 1 was not; this
indicates that the frameshift was the initial mutation.
The Arg467(11-bp ins) mutation was also detectable in
the blood of the father, but the ratio of mutant to wild-
type DNA was less than the 50:50 ratio expected for a
heterozygote carrier (fig. 4). Additional evidence that the
father was a germ-line mosaic came from the observa-
tion, based on intragenic RFLPs, that the father had
passed the same haplotype both to the affected child and
to an unaffected child who did not display the mutation.
Analysis of the father’s semen revealed the frameshift
mutation in a proportion (20%–30%) that was similar
to that found in leukocyte DNA. The same proportion
of mutant DNA was found both in whole semen and in
purified sperm.
In family 385, analysis of leukocyte DNA from a child
affected with bilateral retinoblastoma indicated a 21-bp
deletion that began at the third base of intron 15
Sippel et al.: Mosaicism in Retinoblastoma 615
Figure 4 Analysis of the frameshift mutation Arg467(11-bp ins)
in family 139. SSCP results of analysis of leukocyte DNA appear di-
rectly below the symbol for each individual, except for lanes under
the father (unblackened square) and the affected son (blackened
square), where B indicates leukocyte DNA; S, semen DNA; and T,
tumor DNA. The affected son displays approximately equal amounts
of mutant and normal DNA in blood and tumor. Unaffected family
members display only the wild-type sequence, with the exception of
the father, who displays the mutant band in both blood and semen,
but at a reduced intensity. The lanes under the terms “40%,” “30%,”
“20%,” and “10%” show results from mixtures of wild-type and
mutant DNA (derived from the unaffected daughter’s leukocytes and
the affected son’s tumor, respectively) that would contain the indicated
proportions of mutant and wild-type alleles. On the basis of these
lanes, we estimate the proportion of mutant sperm in the father’s semen
to be ∼20%–30%.
(76923de121bp). The unaffected father also exhibited
the mutation in leukocyte DNA, but the ratio of mutant
to wild-type sequence was less than the 50:50 ratio ex-
pected for a heterozygote carrier. RFLP analysis, per-
formed with intragenic DNA polymorphisms, indicated
that the father had passed the same haplotype both to
the affected child and to an unaffected child who did
not carry the mutation.
In family 345, a bilaterally affected child heterozy-
gously carried a frameshift mutation, Ser648(1-bp del)
(153335delT). The unaffected mother also carried this
mutation, but the ratio of mutant to wild-type sequence
was less than the 50:50 ratio expected for a heterozygote
carrier. Intragenic RFLPs demonstrated that the mother
had passed the same haplotype both to the affected child
and to an unaffected child who did not carry the
mutation.
Discussion
We confined our search for mosaicism to families in
which the initial mutation in RB1 had been identified.
This was done because, in most cases, mosaicism can be
unsuspected, or impossible to prove, unless the respon-
sible gene defect in a family is known and pertinent
family members are available for analysis. In fact, prior
to DNA analysis, mosaicism could have been suspected
in only 2 of the 15 families with a documented mosaic
member. These were families 262 and 296, in which
unaffected parents had more than one affected child.
Even in these two families, it was only after the initial
mutation was discovered and analyzed that the possi-
bility that one parent was a nonpenetrant, homogeneous
carrier was ruled out.
In 15 (∼10%) of the 156 families in our survey, mo-
saicism was documented in a family member. In addi-
tion, there were many families with one member who
was likely, but could not be proved, to be mosaic. As
demonstrated in family 262, absence of an initial mu-
tation in leukocyte DNA does not rule out germ-line
mosaicism; in this situation, mosaicism would be rec-
ognized only if the mosaic parent had another child who
inherited the mutation or if germ-line DNA were avail-
able for analysis. In some cases, mosaicism could not be
proved because key family members were unavailable,
unwilling to be analyzed, or deceased. Hence, the actual
proportion of retinoblastoma families with a mosaic
member is likely to be higher than the 10% reported
here.
As a group, the mosaic individuals identified in the
present study exhibited an expected reduced penetrance
and expressivity. Six (40%) of the 15 mosaics did not
have retinoblastoma, and 2 (13%) developed unilateral
retinoblastoma. This contrasts with published values for
the penetrance and severity of hereditary retinoblastoma
(Vogel 1979) that indicate that only ∼10% of carriers
are unaffected, ∼30% are unilaterally affected, and the
remainder are bilaterally affected ( ; ;2x  16.9 df  2
). Carlson and Desnick (1979) proposed thatP ! .001
mutational mosaicism was the explanation for variable
expressivity in retinoblastoma patients. According to
this model, reduced expressivity in patients who are mo-
saics for a retinoblastoma-predisposingmutation reflects
the fact that fewer cells are targets for a secondmutation.
Mosaicism may also explain the anticipation that has
been reported in some families with retinoblastoma
(Schappert-Kimmijser et al. 1966); the larger proportion
of bilateral retinoblastoma compared with unilateral re-
tinoblastoma in the second generation of two-generation
pedigrees may reflect a high frequency of mosaicism and,
consequently, lower penetrance in the affected founder
in the first generation. Mosaicism is an established cause
of phenotypic variation in the expression of other genetic
diseases (Hall 1988). For example, a milder clinical pres-
entation has been reported in mosaic individuals who
have mutations in the genes for type 1 or type 2 neu-
rofibromatosis (Bourn et al. 1994; Colman et al. 1996).
A review of the literature reveals a number of previous
reports of mosaicism in retinoblastoma; most of these
reports describe one or only a few cases (Munier et al.
1988; Greger et al. 1990; Shimizu et al. 1994; Blanquet
et al. 1995; Lohmann et al. 1997). A survey (Munier et
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al. 1988) of published case reports of cytogenetically
detectable chromosome 13 deletions in patients with re-
tinoblastoma found that 25 (20%) of 126 reported in-
dividuals were mosaics. Of course, a literature review
provides only an approximate value for the incidence of
mosaicism because of the inherent biases in reporting
such cases. However, this tabulation of mosaics with
cytogenetically detectable abnormalities is noteworthy
because it corroborates our impression, based mainly on
cases with mutations that are beyond the resolution of
cytogenetic techniques, that mosaicism among families
with retinoblastoma is not rare.
The incidence of mosaicism should be high in diseases,
such as retinoblastoma, in which (1) a large proportion
of all cases represent new mutations, (2) substantial so-
matic mosaicism can occur in a parent with a normal
phenotype, and (3) there is no strong paternal age effect
(Wijsman 1991). However, data from which one can
estimate the actual incidence of mosaicism have been
obtained for very few diseases. Duchenne muscular dys-
trophy, another disease with a high new-mutation rate
(Vogel and Rathenberg 1975), is notable in this regard.
In a study of 41 families with an identified mutation, a
mosaic member could be identified in 7 (17%) (Bakker
et al. 1989). Another study used serum creatinine kinase
levels to infer that ∼12% of females with no prior history
of Duchenne dystrophy, but with two or more carrier
or affected offspring, are mosaics (Passos-Bueno et al.
1990).
Our experience indicates that the high frequency of
mosaicism is unrecognized by many genetic counselors
and clinicians who care for families with retinoblastoma.
When genetic counseling is provided to patients and
family members, mosaicism is often not empha-
sized—partly because of the uncertainties in recurrence
risks that mosaicism produces and partly because of the
difficulty of explaining mosaicism clearly to patients
who are unfamiliar with the principles of genetics. Be-
cause of the substantial incidence of mosaicism reported
here, the possibility of mosaicism should be entertained
whenever a family with an isolated case of retinoblas-
toma is identified. Specific revisions to the traditional
ways in which patients with retinoblastoma are cate-
gorized (Vogel 1979), cared for, and counseled are pre-
sented below.
1. In a unilateral, simplex case of retinoblastoma, ab-
sence of a detected mutation in leukocytes does not re-
liably predict that no tumors will arise in the fellow eye
in the future. It has been customary for children with
unilateral, simplex retinoblastoma to be examined fre-
quently for tumors that might arise in the fellow eye.
During the first 3-5 years of life, when retinoblastomas
are most prone to arise, many children are not suffi-
ciently cooperative to allow thorough examination of
their retinas. At many retinoblastoma clinics, eye ex-
aminations of young children are performed under gen-
eral anesthesia. After the identification of RB1 (Friend
et al. 1986; Toguchida et al. 1993) and the subsequent
availability of molecular genetic analysis of patients
(Wiggs et al. 1988; Dunn et al. 1989; Yandell et al. 1989;
Hogg et al. 1992; Shimizu et al. 1994; Blanquet et al.
1995; Lohmann et al. 1996), it was hoped that patients
who had unilateral simplex retinoblastoma, without a
germ-line mutation, could be identified and spared re-
peated exposures to general anesthesia (Wiggs and Dryja
1988; Noorani et al. 1996). The cases reported here
(families 294, 377, and 266) and elsewhere (Lohmann
et al. 1997) indicate that, even when an initial mutation
is identified in the tumor from the first affected eye and
analysis of leukocyte DNA does not detect the mutation,
children are still at risk for development of a tumor in
the fellow eye. Our three examples are derived from 60
originally unilateral simplex cases in which an identified
initial mutation was absent from leukocyte DNA. On
the basis of these cases, the estimated risk for developing
a tumor in the fellow eye is ∼5%. This figure makes it
advisable to continue to closely monitor the eyes of chil-
dren with unilateral retinoblastoma, regardless of the
results of leukocyte DNA analysis.
2. Some bilateral simplex retinoblastoma patients and
unilateral, multifocal simplex retinoblastoma patients
have a recurrence risk among their offspring that is much
less than 45%–50%. Previous studies that combine data
from many cases have found that ∼45%–50% of the
offspring of patients with bilateral simplex retinoblas-
toma developed retinoblastoma. These data prompted
the conclusions that all bilaterally affected patients are
germ-line carriers and that the occasional nonpenetrant-
carrier offspring explain the transmission ratio of slightly
less than 50% (Vogel 1979). Here, however, we describe
mosaic, bilaterally affected patients who have an initial
mutation that either is present in only a fraction of leu-
kocytes (families 7, 26, 218, and 452) or is not detectable
in leukocytes at all (families 294, 377, and 266). It is
likely that the germ line in these individuals is either
mosaic or free of the mutation. Evidence for a reduced
abundance of mutant germ cells comes from three mo-
saics who have reproduced (families 26, 218, and 452).
Of the nine offspring in these three families, only two
were carriers, and only these two were affected; hap-
lotype analysis indicated that three others (one in family
26 and two in family 452) inherited the haplotype as-
sociated with the mutation but did not inherit the mu-
tation itself.
These cases require modification of the dictum that
all bilaterally affected patients are germ-line carriers. It
is still uncertain whether, in bilaterally affected mosaics,
the proportion of mutant to wild-type DNA in leuko-
cytes is a useful predictor of the proportion of mutant
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germ cells. Whenever possible (e.g., in male mosaics), it
is best to base the recurrence risk estimate on an analysis
of germ-line DNA. In this regard, it should be noted that
the germ line may not be stable. In patients with chro-
mosomal mosaicism for 13q deletions that cause reti-
noblastoma, the percentage of lymphocytes that have
the cytogenetic abnormality changes over time (Orye et
al. 1982; Motegi andMinoda 1984; Ribeiro et al. 1988).
The possibility that the proportion of spermatozoa that
carry an RB1 mutation also changes over time warrants
further investigation. For the purpose of recurrence risk
estimation, it is advisable for now to perform germ-line
analysis as close as possible to the time period during
which a couple wants to conceive a child.
3. It is possible—but not yet proven—that every bi-
lateral or unilateral retinoblastoma patient in whom an
initial mutation is identified in tumor cells, but not in
leukocytes, has a recurrence risk of zero. Every germ-
line mosaic reported here and elsewhere (Munier et al.
1988; Greger et al. 1990) had an initial mutation that
was detectable in leukocyte DNA. Whether the converse
is true—whether the germ line is never involved in af-
fected individuals without an identified initial mutation
in leukocyte DNA—remains an open question. Of our
three (all bilaterally) affected patients with an identified
initial mutation that was not detected in leukocyteDNA,
none has reproduced, and, to our knowledge, no com-
parable individuals who have reproduced have yet been
reported by others. Two of the three patients we report
are males, but they are too young to provide germ-line
DNA for analysis. Future identification, evaluation, and
follow-up of many such patients are required to deter-
mine whether they can be considered to have no recur-
rence risk. Besides the importance for genetic counseling,
this might have implications regarding the pattern of
human embryonic development. Perhaps the retinal an-
lage is separated from the precursors of leukocytes and
germ cells early in embryogenesis.
4. If unaffected parents with no previous family his-
tory of retinoblastoma have an affected child, DNA-
based estimates of the recurrence risk for future children
should include, whenever possible, an analysis of pater-
nal germ-line DNA. After reviewing data published prior
to the availability of mutation-detection techniques, Vo-
gel (1979) estimated the recurrence risk to a child born
with simplex retinoblastoma at ∼6%, if the retinoblas-
toma was bilateral, and at ∼1%, if the retinoblastoma
was unilateral. These recurrence risks were postulated
to stem from the possibility that one parent was an
asymptomatic carrier or a mosaic. The results of the
present study indicate that a major portion of the re-
currence risk in these situations comes from germ-line
mosaicism in one of the parents.
In simplex cases in which an initial mutation is iden-
tified, recurrence risk among siblings of the affected in-
dividual is negligible if the affected individual is mosaic.
On the other hand, whenever the index case is found to
carry a new germ-line mutation homogeneously, the re-
currence risk is elevated. Measurement of that risk re-
quires evaluation of the parents, who may be homoge-
neous carriers or germ-line mosaics. As demonstrated in
family 262, reliable estimates of recurrence risks may
require analysis of germ-line DNA. Since ∼85% of new
germ-line mutations in RB1 arise in the paternally de-
rived allele (Dryja et al. 1997), and since germ-line DNA
is noninvasively procurable from fathers, evaluation for
germ-line mosaicism, in most cases, will focus on fathers.
5. The risk that a patient with unilateral simplex ret-
inoblastoma will have mutant germ cells may be much
higher than 12%; however, some will be mosaics, and
!50% of their germ cells will be mutant. Patients with
unilateral simplex retinoblastoma are traditionally con-
sidered to be either noncarriers, with no risk of having
affected children, or carriers, with a 50% recurrence risk
for each offspring (Vogel 1979). The calculated relative
proportions of each type (88% noncarriers, 12% car-
riers) were based on retrospective surveys of the off-
spring of patients in this category; these surveys have
shown, among these patients’ offspring, a retinoblas-
toma recurrence risk of 5%–6%. In light of our obser-
vations and those of Lohmann et al. (1997), these values
must be revised. The 156 families in our study included
80 in which the first affected individual had unilateral
retinoblastoma. The initial mutation was detected in leu-
kocyte DNA from 23 individuals, including 2 who were
proven to be mosaics (families 333 and 344), in whom
a mutation was detected in a fraction of leukocytes. On
the basis of an analysis of leukocyte DNA from 36 uni-
lateral simplex retinoblastoma patients with an identi-
fied initial mutation, Lohmann et al. (1997) found 6 in
whom the initial mutation was detected in leukocytes,
and in 1 of these, somatic mosaicism could be docu-
mented. These numbers provide a rough estimate of the
proportion (∼25%) of newly diagnosed, unilateral sim-
plex retinoblastoma patients who are either homoge-
neous carriers or mosaics. Ascertainment biases make
this number very approximate. For example, there is a
bias against including cases in which no tumor DNA is
available for analysis, since identification of an initial
mutation is less likely in these cases. However, the in-
cidence of mosaicism among unilateral simplex cases, as
among bilateral simplex cases, is undoubtedly substan-
tial. Mosaicism in retinoblastoma must be given serious
consideration, both for scheduling follow-up eye ex-
aminations for young children and for genetic
counseling.
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